Wednesday, August 27, 2025
Cognition Therapeutics $30 M Registered Direct Offering
Cognition Therapeutics (NASDAQ: CGTX) has announced a $30 million registered direct offering of common stock, involving the sale of 14,700,000 shares to two new fundamental institutional investors, including a prominent global investment manager.
The offering is expected to close around August 29, 2025, with Titan Partners Group acting as the sole placement agent. The proceeds will fund the preparation of Phase 3 programs for zervimesine in neurodegenerative disorders, along with working capital and general corporate purposes.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.